Johnson & Johnson CEO Announces Company Will Not Enter Obesity Drug Market
Johnson & Johnson (JNJ) announced it will not enter the GLP-1 obesity drug market despite its booming popularity. The decision was made by CEO Joaquin Duato, who emphasized focusing on cancer and brain disease instead. J&J's stock is near record highs as the company shifts strategy to capitalize on areas of strength.
Topics: cancer research executive strategy GLP-1 obesity drugs pharmaceuticals